Published in J Biol Chem on August 31, 2010
JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity (2012) 2.85
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab (2012) 1.56
Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A (2011) 1.48
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One (2011) 1.29
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel) (2014) 1.17
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol (2012) 1.03
HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res (2014) 1.00
CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem (2011) 1.00
Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. ChemMedChem (2011) 0.99
STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro. J Biomed Res (2012) 0.91
Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res (2015) 0.90
Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo. J Biol Chem (2014) 0.87
A Resveratrol Analogue Promotes ERKMAPK-Dependent Stat3 Serine and Tyrosine Phosphorylation Alterations and Antitumor Effects In Vitro against Human Tumor Cells. Mol Pharmacol (2015) 0.83
Bioactive sesquiterpene lactones and other compounds isolated from Vernonia cinerea. Fitoterapia (2013) 0.79
A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells. JAKSTAT (2012) 0.79
Genetic Interactions of STAT3 and Anticancer Drug Development. Cancers (Basel) (2014) 0.79
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal (2017) 0.75
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol (2006) 6.38
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 6.28
Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature (1998) 5.04
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J (1990) 4.28
Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 4.22
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 3.96
STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 3.75
Tools for comparative protein structure modeling and analysis. Nucleic Acids Res (2003) 3.68
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A (2005) 3.46
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
Validating Stat3 in cancer therapy. Nat Med (2005) 2.96
Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci U S A (1995) 2.92
Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells. Mol Cell Biol (1985) 2.87
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets (2004) 2.21
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol (2002) 2.09
Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol (1999) 1.80
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J Med Chem (2005) 1.62
Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem (2000) 1.61
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett (2003) 1.46
Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem (2008) 1.38
Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res (2000) 1.30
Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem (2008) 1.21
Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. Biochemistry (1994) 1.21
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. ACS Med Chem Lett (2010) 1.18
Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett (2007) 1.18
Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther (2010) 1.12
Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs (2006) 1.11
Src homology-2 domains: structure, mechanisms, and drug discovery. Biopolymers (1998) 1.08
Prolactin and interleukin-2 receptors in T lymphocytes signal through a MGF-STAT5-like transcription factor. Endocrinology (1995) 1.00
Medullary epithelial cell lines from murine thymus constitutively secrete IL-1 and hematopoietic growth factors and express class II antigens in response to recombinant interferon-gamma. Cell Immunol (1989) 0.95
Monocarboxylic-based phosphotyrosyl mimetics in the design of GRB2 SH2 domain inhibitors. Bioorg Med Chem Lett (1999) 0.79
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol (2011) 2.28
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A (2005) 2.00
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther (2006) 1.69
Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res (2010) 1.60
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J (2002) 1.43
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res (2008) 1.43
Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol (2005) 1.39
Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem (2008) 1.38
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One (2011) 1.29
Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem (2008) 1.21
Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem (2009) 1.20
Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene (2004) 1.19
Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg Med Chem Lett (2007) 1.15
The R(h)oads to Stat3: Stat3 activation by the Rho GTPases. Exp Cell Res (2011) 1.12
Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther (2010) 1.12
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem (2012) 1.03
Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomedicine (2012) 1.01
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett (2011) 1.00
Stat3 is required for full neoplastic transformation by the Simian Virus 40 large tumor antigen. Mol Biol Cell (2005) 0.99
Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. ChemMedChem (2011) 0.99
The RhoU/Wrch1 Rho GTPase gene is a common transcriptional target of both the gp130/STAT3 and Wnt-1 pathways. Biochem J (2009) 0.94
Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp Cell Res (2007) 0.93
Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chem (2010) 0.90
Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun (Camb) (2009) 0.85
Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies. ACS Med Chem Lett (2010) 0.85
A New Metabolite with a Unique 4-Pyranone-γ-Lactam-1,4-Thiazine Moiety from a Hawaiian-Plant Associated Fungus. Org Lett (2015) 0.83
An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery. Biomaterials (2011) 0.83
Differential effects of Stat3 inhibition in sparse vs confluent normal and breast cancer cells. Cancer Lett (2005) 0.81
THAP5 is a DNA-binding transcriptional repressor that is regulated in melanoma cells during DNA damage-induced cell death. Biochem Biophys Res Commun (2010) 0.81
Artificially induced protein-membrane anchorage with cholesterol-based recognition agents as a new therapeutic concept. Angew Chem Int Ed Engl (2011) 0.79
Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma. J Med Chem (2015) 0.78
Buffer-stable chitosan-polyglutamic acid hybrid nanoparticles for biomedical applications. Macromol Biosci (2013) 0.77
Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. Leuk Lymphoma (2013) 0.77
In situ electroporation of large numbers of cells using minimal volumes of material. Anal Biochem (2003) 0.77